Sensei Biotherapeutics, Inc. (SNSE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Sensei Biotherapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Sensei Biotherapeutics, Inc. (SNSE) has returned 195.41% so far this year and 300.00% over the past 12 months.

Based on dividend-adjusted daily data since Feb 4, 2021, SNSE's average daily return is +0.06%, while the average monthly return is -0.87%.

Historically, 31% of months were positive and 69% were negative. The best month was Feb 2026 with a return of +221.1%, while the worst month was Mar 2022 at -36.0%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 8 months.

On a daily basis, SNSE closed higher 43% of trading days. The best single day was Feb 18, 2026 with a return of +187.5%, while the worst single day was May 24, 2024 at -45.5%.

Sensei Biotherapeutics, Inc. has an annualized alpha of 3.91%, beta of 1.06, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since February 05, 2021.

• This stock participated in 90.65% of S&P 500 Index downside but only -75.90% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

SNSE ranks 89 for risk / return — in the top 89% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Sensei Biotherapeutics, Inc. (SNSE) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Sensei Biotherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Sensei Biotherapeutics, Inc. was 98.73%, occurring on Apr 4, 2025. The portfolio has not yet recovered.

The current Sensei Biotherapeutics, Inc. drawdown is 93.07%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Sensei Biotherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Sensei Biotherapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.